FCSK

Across TCGA pan-cancer cohorts, FCSK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FCSK data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FCSK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FCSK expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where FCSK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.649	0.407	<.001	79	view →
CCRCC	OS	Quartile	II,III,IV	0.985	0.104	.024	15	view →
LSCC	OS	Tertile	All	0.779	0.932	.019	11	view →
LUAD	OS	Median	II,III,IV	0.908	0.339	.003	8	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	6	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FCSK–PDAC (OS)

Open the PDAC breakdown →